Jessica Read

2.2k total citations · 1 hit paper
11 papers, 1.6k citations indexed

About

Jessica Read is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jessica Read has authored 11 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jessica Read's work include Lung Cancer Diagnosis and Treatment (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Jessica Read is often cited by papers focused on Lung Cancer Diagnosis and Treatment (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Jessica Read collaborates with scholars based in United Kingdom, United States and Brazil. Jessica Read's co-authors include Peter Langmuir, Robert F. Gagel, Samuel A. Wells, Henning Dralle, Éric Baudin, James R. Vasselli, Bruce G. Robinson, James A. Fagin, Martin Schlumberger and Massimo Santoro and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Pharmacokinetics and Bioconjugate Chemistry.

In The Last Decade

Jessica Read

11 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

2011 1.1k citations Samuel A. Wells, Bruce G. Robinson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jessica Read United Kingdom	9	762	733	514	428	247	11	1.6k
John Chung United States	11	1.1k 1.4×	477 0.7×	223 0.4×	329 0.8×	156 0.6×	14	1.6k
Maryann Redlinger United States	14	453 0.6×	525 0.7×	193 0.4×	459 1.1×	167 0.7×	25	1.1k
Alessandra Spitale Switzerland	11	791 1.0×	608 0.8×	236 0.5×	187 0.4×	116 0.5×	22	1.5k
Ramona Dadu United States	30	1.8k 2.4×	1.5k 2.0×	396 0.8×	477 1.1×	391 1.6×	94	2.9k
Agnieszka Czarniecka Poland	19	1.0k 1.4×	221 0.3×	141 0.3×	462 1.1×	84 0.3×	69	1.5k
Sofia Paul United States	11	308 0.4×	1.8k 2.5×	1.9k 3.7×	464 1.1×	95 0.4×	24	2.7k
Yong Mee Cho South Korea	22	206 0.3×	449 0.6×	807 1.6×	687 1.6×	107 0.4×	100	1.8k
Dhaval Patel United States	28	713 0.9×	620 0.8×	129 0.3×	570 1.3×	587 2.4×	91	2.1k
Jaume Capdevila Spain	18	758 1.0×	277 0.4×	158 0.3×	150 0.4×	94 0.4×	41	1.0k
A. Fornasiero Italy	17	238 0.3×	700 1.0×	323 0.6×	141 0.3×	390 1.6×	43	1.6k

Countries citing papers authored by Jessica Read

Since Specialization

Citations

This map shows the geographic impact of Jessica Read's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica Read with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica Read more than expected).

Fields of papers citing papers by Jessica Read

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica Read. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica Read. The network helps show where Jessica Read may publish in the future.

Co-authorship network of co-authors of Jessica Read

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica Read. A scholar is included among the top collaborators of Jessica Read based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica Read. Jessica Read is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Ackerley, Suzanne, Neil Wilson, Paul Boland, Jessica Read, & Louise Connell. (2023). Implementation of neurological group-based telerehabilitation within existing healthcare during the COVID-19 pandemic: a mixed methods evaluation. BMC Health Services Research. 23(1). 671–671. 5 indexed citations

Davis, John A., Mark Kagan, Jessica Read, Markus Walles, & Panos Hatsis. (2017). Immunoprecipitation Middle-Up LC–MS for In Vivo Drug-To-Antibody Ratio Determination for Antibody–Drug Conjugates. Bioanalysis. 9(20). 1535–1549. 13 indexed citations

Grünewald, Jan, Yunho Jin, Jessica Read, et al.. (2017). Optimization of an Enzymatic Antibody–Drug Conjugation Approach Based on Coenzyme A Analogs. Bioconjugate Chemistry. 28(7). 1906–1915. 15 indexed citations

Johansson, Susanne, Jessica Read, Stuart Oliver, et al.. (2014). Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine. Clinical Pharmacokinetics. 53(9). 837–847. 52 indexed citations

Wells, Samuel A., Bruce G. Robinson, Robert F. Gagel, et al.. (2011). Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 30(2). 134–141. 1082 indexed citations breakdown →

Martin, Paul, et al.. (2011). Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole. Drugs in R&D. 11(1). 37–51. 40 indexed citations

Boer, Richard H. De, Óscar Arrieta, James Chih‐Hsin Yang, et al.. (2011). Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 29(8). 1067–1074. 230 indexed citations

Martin, Paul, et al.. (2011). Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole. Drugs in R&D. 11(1). 37–51. 1 indexed citations

Martin, Paul, et al.. (2010). Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment. Clinical Pharmacokinetics. 49(9). 607–618. 26 indexed citations

10.

Wells, Samuel A., Bruce G. Robinson, Robert F. Gagel, et al.. (2010). Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA).. Journal of Clinical Oncology. 28(15_suppl). 5503–5503. 48 indexed citations

11.

Boer, R. de, Óscar Arrieta, Maya Gottfried, et al.. (2009). Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). Journal of Clinical Oncology. 27(15_suppl). 8010–8010. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact